New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:05 EDTSQNMSequenom receives FDA premarket clearance
Sequenom announced that it has received premarket 510k clearance from the FDA to market its IMPACT Dx Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx System. The IMPACT Dx Factor V Leiden and Factor II Genotyping Test is performed on the IMPACT Dx System, and is indicated for use as an aid in the diagnosis of patients with suspected thrombophilia. As previously announced, Sequenom completed the sale of its Bioscience business segment to Agena Bioscience. As part of this sale, the Premarket 510k Notification will transfer to Agena Bioscience and Sequenom will receive $2M upon the achievement of this regulatory milestone.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
08:39 EDTSQNMSequenom should be bought following solid Q2, says Maxim
Subscribe for More Information
July 29, 2014
18:35 EDTSQNMOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTSQNMSequenom reports Q2 adjusted EPS (7c), consensus (11c)
Subscribe for More Information
16:32 EDTSQNMSequenom enters license agreement with Mayo Medical Laboratories
Subscribe for More Information
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use